Standard BioTools Inc. (NASDAQ:LAB) Stock Holdings Lessened by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in shares of Standard BioTools Inc. (NASDAQ:LAB) by 19.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 306,871 shares of the company’s stock after selling 75,617 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Standard BioTools were worth $592,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Xponance Inc. acquired a new stake in shares of Standard BioTools during the 2nd quarter valued at $34,000. Nisa Investment Advisors LLC increased its stake in shares of Standard BioTools by 433.8% in the third quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock worth $35,000 after acquiring an additional 14,732 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in shares of Standard BioTools during the second quarter worth $39,000. Creative Planning acquired a new stake in Standard BioTools during the third quarter valued at $39,000. Finally, Algert Global LLC acquired a new stake in Standard BioTools during the second quarter valued at $44,000. 53.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, TD Cowen cut their price target on Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.

Standard BioTools Stock Up 0.8 %

NASDAQ LAB opened at $2.00 on Friday. The stock has a market capitalization of $744.52 million, a PE ratio of -2.82 and a beta of 1.61. Standard BioTools Inc. has a 12-month low of $1.21 and a 12-month high of $3.04. The company has a 50 day moving average price of $1.87 and a two-hundred day moving average price of $1.94.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.